These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15705003)

  • 1. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.
    Goff DC; Cather C; Evins AE; Henderson DC; Freudenreich O; Copeland PM; Bierer M; Duckworth K; Sacks FM
    J Clin Psychiatry; 2005 Feb; 66(2):183-94; quiz 147, 273-4. PubMed ID: 15705003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC).
    De Hert M; Dekker JM; Wood D; Kahl KG; Holt RI; Möller HJ
    Eur Psychiatry; 2009 Sep; 24(6):412-24. PubMed ID: 19682863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular disease and sudden death in schizophrenia.
    Davidson M
    J Clin Psychiatry; 2002; 63 Suppl 9():5-11. PubMed ID: 12088174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?
    Wildgust HJ; Beary M
    J Psychopharmacol; 2010 Nov; 24(4 Suppl):37-50. PubMed ID: 20923919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.
    Newcomer JW
    J Clin Psychiatry; 2009; 70 Suppl 3():30-6. PubMed ID: 19570499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of a health network in secondary prevention among coronary patients].
    Denolle T; Sharareh A; Dib M; Agaesse MF; Auguste V; Boutier H; Bouvet C; Maillard J; Richard A; Revault d'allonnes F
    Arch Mal Coeur Vaiss; 2007 Aug; 100(8):625-9. PubMed ID: 17928764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excess medical comorbidity and mortality across the lifespan in schizophrenia.: A nationwide Danish register study.
    Brink M; Green A; Bojesen AB; Lamberti JS; Conwell Y; Andersen K
    Schizophr Res; 2019 Apr; 206():347-354. PubMed ID: 30527270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study.
    Howard BV; Lee ET; Cowan LD; Devereux RB; Galloway JM; Go OT; Howard WJ; Rhoades ER; Robbins DC; Sievers ML; Welty TK
    Circulation; 1999 May; 99(18):2389-95. PubMed ID: 10318659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Higher mortality and somatic illness in a psychotic diseases].
    Lindh Å; Gothefors D; Runeson B
    Lakartidningen; 2015 Oct; 112():. PubMed ID: 26461503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of cardiovascular disease risk factors in patients from Croatian Zagorje County treated at Department of Medicine, Zabok General Hospital from 2000 to 2006.
    Pesek K; Pesek T; Rados M; Buković D; Fures R; Cuk V
    Coll Antropol; 2007 Sep; 31(3):709-15. PubMed ID: 18041378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal trends in cardiovascular disease risk factor profiles in a population-based schizophrenia sample: a repeat cross-sectional study.
    Chiu M; Rahman F; Vigod S; Wilton AS; Kurdyak P
    J Epidemiol Community Health; 2018 Jan; 72(1):71-77. PubMed ID: 29061843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
    Smith SC; Blair SN; Bonow RO; Brass LM; Cerqueira MD; Dracup K; Fuster V; Gotto A; Grundy SM; Miller NH; Jacobs A; Jones D; Krauss RM; Mosca L; Ockene I; Pasternak RC; Pearson T; Pfeffer MA; Starke RD; Taubert KA
    J Am Coll Cardiol; 2001 Nov; 38(5):1581-3. PubMed ID: 11691544
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary prevention of cardiovascular disease: a call to action.
    Bonow RO
    Circulation; 2002 Dec; 106(25):3140-1. PubMed ID: 12485965
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population?
    Castillo-Sánchez M; Fàbregas-Escurriola M; Bergè-Baquero D; Fernández-SanMartín M; Goday-Arno A
    Clin Exp Hypertens; 2017; 39(5):441-447. PubMed ID: 28590147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.
    De Hert M; Vancampfort D; Correll CU; Mercken V; Peuskens J; Sweers K; van Winkel R; Mitchell AJ
    Br J Psychiatry; 2011 Aug; 199(2):99-105. PubMed ID: 21804146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
    Lynn MM
    Adv Nurse Pract; 2000 Jun; 8(6):36-41; quiz 42-3. PubMed ID: 15658206
    [No Abstract]   [Full Text] [Related]  

  • 18. High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey.
    Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Minami Y; Okamoto K; Sagae T; Someya T
    PLoS One; 2016; 11(11):e0166429. PubMed ID: 27855222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice].
    Royo-Bordonada MÁ; Armario P; Lobos Bejarano JM; Pedro-Botet J; Villar Alvarez F; Elosua R; Brotons Cuixart C; Cortés O; Serrano B; Cammafort Babkowski M; Gil Núñez A; Pérez A; Maiques A; de Santiago Nocito A; Castro A; Alegría E; Baeza C; Herranz M; Sans S; Campos P;
    Hipertens Riesgo Vasc; 2017; 34(1):24-40. PubMed ID: 28017552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.